Edgewise Therapeutics to Host Webcast Event to Discuss Top-Line Results from Phase 2 CIRRUS-HCM 28-Day Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) on Wednesday, April 2 at 8:30 am Eastern Time

Group 1 - Edgewise Therapeutics will hold a live webcast on April 2, 2025, to discuss top-line data of EDG-7500 from the Phase 2 CIRRUS-HCM trial [1] - The webcast will feature two leading investigators in the field of hypertrophic cardiomyopathy (HCM) [1] - An accompanying slide presentation will be available for participants [1] Group 2 - EDG-7500 is a novel oral, selective cardiac sarcomere modulator aimed at addressing impaired cardiac relaxation in HCM and other diastolic dysfunction diseases [2] - The drug is currently in Phase 2 clinical development [2][3] - Edgewise Therapeutics is focused on developing therapeutics for muscular dystrophies and serious cardiac conditions, with a commitment to improving patient lives [3]